Modification of the Linker Amino Acid in the Cell-Penetrating Peptide NickFect55 Leads to Enhanced pDNA Transfection for In Vivo Applications

• Published in: Pharmaceutics Vol. 15; no. 3; p. 883
• Main Authors: Härk, Heleri H, Porosk, Ly, de Mello, Lucas R, Arukuusk, Piret, da Silva, Emerson R, Kurrikoff, Kaido
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-03-2023; MDPI
• Subjects: Amino acids; Analysis; Care and treatment; cell-penetrating peptides; Chromatography; Health aspects; in vivo transfection; Lung cancer; Molecular weight; Nanoparticles; pDNA delivery; Peptides; Structure; Transfection; Estonia; Sweden; United Kingdom > UK; United States > US; Germany; in vivo transfection; pDNA delivery; cell-penetrating peptides
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15030883

Despite numerous efforts over the last three decades, nucleic acid-based therapeutics still lack delivery platforms in the clinical stage. Cell-penetrating peptides (CPPs) may offer solutions as potential delivery vectors. We have previously shown that designing a "kinked" structure in the peptide backbone resulted in a CPP with efficient in vitro transfection properties. Further optimization of the charge distribution in the C-terminal part of the peptide led to potent in vivo activity with the resultant CPP NickFect55 (NF55). Currently, the impact of the linker amino acid was further investigated in the CPP NF55, with the aim to discover potential transfection reagents for in vivo application. Taking into account the expression of the delivered reporter in the lung tissue of mice, and the cell transfection in the human lung adenocarcinoma cell line, the new peptides NF55-Dap and NF55-Dab* have a high potential for delivering nucleic acid-based therapeutics to treat lung associated diseases, such as adenocarcinoma.